Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab
Introduction Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short‐mid term in advanced tumours is unclear. The present analysis investigates the role of BMI weight classes in a large sample of patients affected...
Gespeichert in:
| Veröffentlicht in: | Liver international 2024-05, Vol.44 (5), p.1108-1125 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1125 |
|---|---|
| container_issue | 5 |
| container_start_page | 1108 |
| container_title | Liver international |
| container_volume | 44 |
| creator | Rimini, Margherita Stefanini, Bernardo Tada, Toshifumi Suda, Goki Shimose, Shigeo Kudo, Masatoshi Finkelmeier, Fabian Yoo, Changhoon Presa, José Amadeo, Elisabeth genovesi, Virginia De Grandis, Maria Caterina Iavarone, Massimo Marra, Fabio Foschi, Francesco Tamburini, Emiliano Rossari, Federico Vitiello, Francesco Bartalini, Linda Soldà, Caterina Tovoli, Francesco Vivaldi, Caterina Lonardi, Sara Silletta, Marianna Kumada, Takashi Sakamoto, Naoya Iwamoto, Hideki Aoki, Tomoko Himmelsbach, Vera Montes, Margarida Hiraoka, Atsushi Sho, Takuya Niizeki, Takashi Nishida, Naoshi Steup, Christoph Hirooka, Masashi Kariyama, Kazuya Tani, Joji Atsukawa, Masanori Takaguchi, Koichi Itobayashi, Ei Fukunishi, Shinya Tsuji, Kunihiko Ishikawa, Toru Tajiri, Kazuto Ochi, Hironori Yasuda, Satoshi Toyoda, Hidenori Ogawa, Chikara Nishimura, Takashi Hatanaka, Takeshi Kakizaki, Satoru Shimada, Noritomo Kawata, Kazuhito Tada, Fujimasa Ohama, Hideko Nouso, Kazuhiro Morishita, Asahiro Tsutsui, Akemi Nagano, Takuya Itokawa, Norio Okubo, Tomomi Arai, Taeang Imai, Michitaka Kosaka, Hisashi Naganuma, Atsushi Koizumi, Yohei Nakamura, Shinichiro Kaibori, Masaki Iijima, Hiroko Hiasa, Yoichi Persano, Mara Camera, Silvia Foti, Silvia Aldrighetti, Luca Cascinu, Stefano Casadei‐Gardini, Andrea Piscaglia, Fabio |
| description | Introduction
Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short‐mid term in advanced tumours is unclear. The present analysis investigates the role of BMI weight classes in a large sample of patients affected by HCC and receiving atezolizumab plus bevacizumab or lenvatinib as first‐line treatment.
Methods and Material
The cohort included consecutive patients affected by BCLC‐c and BCLC‐B HCC patients from a multicenter international study group who received atezolizumab plus bevacizumab or lenvatinib as first‐line therapy. Population was stratified according to the BMI in under‐, over‐ and normal‐weight according to the conventional thresholds.
The primary objective of the study was to evaluate the prognostic and predictive impact of BMI in patients affected by advanced or intermediate HCC. Survival curves were estimated using the product‐limit method of Kaplan–Meier. The role of stratification factors was analysed with log‐rank tests.
Results
1292 consecutive patients with HCC were analysed. 466 (36%) patients were treated with lenvatinib and 826 (64%) patients were treated with atezolizumab plus bevacizumab. In the atezolizumab plus bevacizumab arm, 510 (62%) patients were normal‐weight, 52 (6%) underweight and 264 (32%) overweight. At the univariate analysis for OS, underweight patients had significantly shorter OS compared to normal‐weight patients, whereas no differences were found between normal‐weight versus overweight. Multivariate analysis confirmed that underweight patients had significantly shorter OS compared to normal‐weight patients (HR: 1.7; 95% CI: 1.0–2.8; p = .0323). In the lenvatinib arm, 26 patients (5.6%) were categorized as underweight, 256 (54.9%) as normal‐weight, and 184 (39.5%) as overweight. At the univariate analysis for OS, no significant differences were found between normal‐weight versus underweight and between normal‐weight versus overweight, which was confirmed at multivariate analysis.
Conclusion
Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib. |
| doi_str_mv | 10.1111/liv.15885 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2974003972</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2974003972</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3135-f441044af7f38fbda3b871f9f90936ec1c3ded7ca0d12ae4c3519a15618b161f3</originalsourceid><addsrcrecordid>eNp10b1uFDEUBWALEZEQKHgBZIkmFJv4jj1_JVoRstJKaYDW8niugyOPPdgzGzZV6lQ8I0-Cw4QUSLixZX06uleHkDfATiGfM2d3p1A2TfmMHIGomxUvODx_ehf8kLxM6ZoxaNsSXpBD3pRQF011RO43w6j0RIOhXej3dFApUet7_EGDp9M3pGMMVz4kmx7M7CMm1JPqHNKL9ZqOarLop0QjarQ766-osTFNv-5-OuuRbtHvMvG2oyFSNeFtcPZ2HlRHRzcn2uFO6eXjFTkwyiV8_Xgfky_nHz-vL1bby0-b9YftSnPg5coIAUwIZWrDG9P1indNDaY1LWt5hRo077GvtWI9FAqF5iW0CsoKmg4qMPyYnCy5ebPvM6ZJDjZpdE55DHOSRVsLxnhbF5m--4dehzn6PJ3kTDDOq0qIrN4vSseQUkQjx2gHFfcSmHwoSOaC5J-Csn37mDh3A_ZP8m8jGZwt4MY63P8_SW43X5fI312AnT0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3040336644</pqid></control><display><type>article</type><title>Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Rimini, Margherita ; Stefanini, Bernardo ; Tada, Toshifumi ; Suda, Goki ; Shimose, Shigeo ; Kudo, Masatoshi ; Finkelmeier, Fabian ; Yoo, Changhoon ; Presa, José ; Amadeo, Elisabeth ; genovesi, Virginia ; De Grandis, Maria Caterina ; Iavarone, Massimo ; Marra, Fabio ; Foschi, Francesco ; Tamburini, Emiliano ; Rossari, Federico ; Vitiello, Francesco ; Bartalini, Linda ; Soldà, Caterina ; Tovoli, Francesco ; Vivaldi, Caterina ; Lonardi, Sara ; Silletta, Marianna ; Kumada, Takashi ; Sakamoto, Naoya ; Iwamoto, Hideki ; Aoki, Tomoko ; Himmelsbach, Vera ; Montes, Margarida ; Hiraoka, Atsushi ; Sho, Takuya ; Niizeki, Takashi ; Nishida, Naoshi ; Steup, Christoph ; Hirooka, Masashi ; Kariyama, Kazuya ; Tani, Joji ; Atsukawa, Masanori ; Takaguchi, Koichi ; Itobayashi, Ei ; Fukunishi, Shinya ; Tsuji, Kunihiko ; Ishikawa, Toru ; Tajiri, Kazuto ; Ochi, Hironori ; Yasuda, Satoshi ; Toyoda, Hidenori ; Ogawa, Chikara ; Nishimura, Takashi ; Hatanaka, Takeshi ; Kakizaki, Satoru ; Shimada, Noritomo ; Kawata, Kazuhito ; Tada, Fujimasa ; Ohama, Hideko ; Nouso, Kazuhiro ; Morishita, Asahiro ; Tsutsui, Akemi ; Nagano, Takuya ; Itokawa, Norio ; Okubo, Tomomi ; Arai, Taeang ; Imai, Michitaka ; Kosaka, Hisashi ; Naganuma, Atsushi ; Koizumi, Yohei ; Nakamura, Shinichiro ; Kaibori, Masaki ; Iijima, Hiroko ; Hiasa, Yoichi ; Persano, Mara ; Camera, Silvia ; Foti, Silvia ; Aldrighetti, Luca ; Cascinu, Stefano ; Casadei‐Gardini, Andrea ; Piscaglia, Fabio</creator><creatorcontrib>Rimini, Margherita ; Stefanini, Bernardo ; Tada, Toshifumi ; Suda, Goki ; Shimose, Shigeo ; Kudo, Masatoshi ; Finkelmeier, Fabian ; Yoo, Changhoon ; Presa, José ; Amadeo, Elisabeth ; genovesi, Virginia ; De Grandis, Maria Caterina ; Iavarone, Massimo ; Marra, Fabio ; Foschi, Francesco ; Tamburini, Emiliano ; Rossari, Federico ; Vitiello, Francesco ; Bartalini, Linda ; Soldà, Caterina ; Tovoli, Francesco ; Vivaldi, Caterina ; Lonardi, Sara ; Silletta, Marianna ; Kumada, Takashi ; Sakamoto, Naoya ; Iwamoto, Hideki ; Aoki, Tomoko ; Himmelsbach, Vera ; Montes, Margarida ; Hiraoka, Atsushi ; Sho, Takuya ; Niizeki, Takashi ; Nishida, Naoshi ; Steup, Christoph ; Hirooka, Masashi ; Kariyama, Kazuya ; Tani, Joji ; Atsukawa, Masanori ; Takaguchi, Koichi ; Itobayashi, Ei ; Fukunishi, Shinya ; Tsuji, Kunihiko ; Ishikawa, Toru ; Tajiri, Kazuto ; Ochi, Hironori ; Yasuda, Satoshi ; Toyoda, Hidenori ; Ogawa, Chikara ; Nishimura, Takashi ; Hatanaka, Takeshi ; Kakizaki, Satoru ; Shimada, Noritomo ; Kawata, Kazuhito ; Tada, Fujimasa ; Ohama, Hideko ; Nouso, Kazuhiro ; Morishita, Asahiro ; Tsutsui, Akemi ; Nagano, Takuya ; Itokawa, Norio ; Okubo, Tomomi ; Arai, Taeang ; Imai, Michitaka ; Kosaka, Hisashi ; Naganuma, Atsushi ; Koizumi, Yohei ; Nakamura, Shinichiro ; Kaibori, Masaki ; Iijima, Hiroko ; Hiasa, Yoichi ; Persano, Mara ; Camera, Silvia ; Foti, Silvia ; Aldrighetti, Luca ; Cascinu, Stefano ; Casadei‐Gardini, Andrea ; Piscaglia, Fabio</creatorcontrib><description>Introduction
Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short‐mid term in advanced tumours is unclear. The present analysis investigates the role of BMI weight classes in a large sample of patients affected by HCC and receiving atezolizumab plus bevacizumab or lenvatinib as first‐line treatment.
Methods and Material
The cohort included consecutive patients affected by BCLC‐c and BCLC‐B HCC patients from a multicenter international study group who received atezolizumab plus bevacizumab or lenvatinib as first‐line therapy. Population was stratified according to the BMI in under‐, over‐ and normal‐weight according to the conventional thresholds.
The primary objective of the study was to evaluate the prognostic and predictive impact of BMI in patients affected by advanced or intermediate HCC. Survival curves were estimated using the product‐limit method of Kaplan–Meier. The role of stratification factors was analysed with log‐rank tests.
Results
1292 consecutive patients with HCC were analysed. 466 (36%) patients were treated with lenvatinib and 826 (64%) patients were treated with atezolizumab plus bevacizumab. In the atezolizumab plus bevacizumab arm, 510 (62%) patients were normal‐weight, 52 (6%) underweight and 264 (32%) overweight. At the univariate analysis for OS, underweight patients had significantly shorter OS compared to normal‐weight patients, whereas no differences were found between normal‐weight versus overweight. Multivariate analysis confirmed that underweight patients had significantly shorter OS compared to normal‐weight patients (HR: 1.7; 95% CI: 1.0–2.8; p = .0323). In the lenvatinib arm, 26 patients (5.6%) were categorized as underweight, 256 (54.9%) as normal‐weight, and 184 (39.5%) as overweight. At the univariate analysis for OS, no significant differences were found between normal‐weight versus underweight and between normal‐weight versus overweight, which was confirmed at multivariate analysis.
Conclusion
Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib.</description><identifier>ISSN: 1478-3223</identifier><identifier>ISSN: 1478-3231</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.15885</identifier><identifier>PMID: 38517286</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>advanced HCC ; Antibodies, Monoclonal, Humanized ; atezolizumab ; Bevacizumab ; Body Mass Index ; Body size ; Body weight ; Carcinoma, Hepatocellular ; Cohorts ; Humans ; International studies ; lenvatinib BMI ; Liver Neoplasms ; Medical prognosis ; Multivariate analysis ; Overweight ; Phenylurea Compounds ; Prognosis ; Quinolines ; Rank tests ; Stratification ; Thinness ; Underweight ; Weight</subject><ispartof>Liver international, 2024-05, Vol.44 (5), p.1108-1125</ispartof><rights>2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2024 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3135-f441044af7f38fbda3b871f9f90936ec1c3ded7ca0d12ae4c3519a15618b161f3</cites><orcidid>0000-0002-2373-8601 ; 0000-0002-2018-0008 ; 0000-0003-3656-285X ; 0000-0002-0760-3045 ; 0000-0003-2211-495X ; 0000-0003-0098-9106 ; 0000-0002-0976-6761 ; 0000-0002-1652-6168 ; 0000-0002-1882-824X ; 0000-0002-4986-8578 ; 0000-0003-3374-7111 ; 0000-0002-2266-2414 ; 0000-0003-4117-339X ; 0000-0001-8264-1845 ; 0000-0003-0224-7093 ; 0000-0001-8629-0878 ; 0000-0001-8559-9910 ; 0000-0003-2068-8386 ; 0000-0001-7415-5898 ; 0000-0002-8350-1155 ; 0000-0002-4102-3474 ; 0000-0003-3493-6504 ; 0000-0003-3800-5678 ; 0000-0002-4047-2585</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.15885$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.15885$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27926,27927,45576,45577</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38517286$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rimini, Margherita</creatorcontrib><creatorcontrib>Stefanini, Bernardo</creatorcontrib><creatorcontrib>Tada, Toshifumi</creatorcontrib><creatorcontrib>Suda, Goki</creatorcontrib><creatorcontrib>Shimose, Shigeo</creatorcontrib><creatorcontrib>Kudo, Masatoshi</creatorcontrib><creatorcontrib>Finkelmeier, Fabian</creatorcontrib><creatorcontrib>Yoo, Changhoon</creatorcontrib><creatorcontrib>Presa, José</creatorcontrib><creatorcontrib>Amadeo, Elisabeth</creatorcontrib><creatorcontrib>genovesi, Virginia</creatorcontrib><creatorcontrib>De Grandis, Maria Caterina</creatorcontrib><creatorcontrib>Iavarone, Massimo</creatorcontrib><creatorcontrib>Marra, Fabio</creatorcontrib><creatorcontrib>Foschi, Francesco</creatorcontrib><creatorcontrib>Tamburini, Emiliano</creatorcontrib><creatorcontrib>Rossari, Federico</creatorcontrib><creatorcontrib>Vitiello, Francesco</creatorcontrib><creatorcontrib>Bartalini, Linda</creatorcontrib><creatorcontrib>Soldà, Caterina</creatorcontrib><creatorcontrib>Tovoli, Francesco</creatorcontrib><creatorcontrib>Vivaldi, Caterina</creatorcontrib><creatorcontrib>Lonardi, Sara</creatorcontrib><creatorcontrib>Silletta, Marianna</creatorcontrib><creatorcontrib>Kumada, Takashi</creatorcontrib><creatorcontrib>Sakamoto, Naoya</creatorcontrib><creatorcontrib>Iwamoto, Hideki</creatorcontrib><creatorcontrib>Aoki, Tomoko</creatorcontrib><creatorcontrib>Himmelsbach, Vera</creatorcontrib><creatorcontrib>Montes, Margarida</creatorcontrib><creatorcontrib>Hiraoka, Atsushi</creatorcontrib><creatorcontrib>Sho, Takuya</creatorcontrib><creatorcontrib>Niizeki, Takashi</creatorcontrib><creatorcontrib>Nishida, Naoshi</creatorcontrib><creatorcontrib>Steup, Christoph</creatorcontrib><creatorcontrib>Hirooka, Masashi</creatorcontrib><creatorcontrib>Kariyama, Kazuya</creatorcontrib><creatorcontrib>Tani, Joji</creatorcontrib><creatorcontrib>Atsukawa, Masanori</creatorcontrib><creatorcontrib>Takaguchi, Koichi</creatorcontrib><creatorcontrib>Itobayashi, Ei</creatorcontrib><creatorcontrib>Fukunishi, Shinya</creatorcontrib><creatorcontrib>Tsuji, Kunihiko</creatorcontrib><creatorcontrib>Ishikawa, Toru</creatorcontrib><creatorcontrib>Tajiri, Kazuto</creatorcontrib><creatorcontrib>Ochi, Hironori</creatorcontrib><creatorcontrib>Yasuda, Satoshi</creatorcontrib><creatorcontrib>Toyoda, Hidenori</creatorcontrib><creatorcontrib>Ogawa, Chikara</creatorcontrib><creatorcontrib>Nishimura, Takashi</creatorcontrib><creatorcontrib>Hatanaka, Takeshi</creatorcontrib><creatorcontrib>Kakizaki, Satoru</creatorcontrib><creatorcontrib>Shimada, Noritomo</creatorcontrib><creatorcontrib>Kawata, Kazuhito</creatorcontrib><creatorcontrib>Tada, Fujimasa</creatorcontrib><creatorcontrib>Ohama, Hideko</creatorcontrib><creatorcontrib>Nouso, Kazuhiro</creatorcontrib><creatorcontrib>Morishita, Asahiro</creatorcontrib><creatorcontrib>Tsutsui, Akemi</creatorcontrib><creatorcontrib>Nagano, Takuya</creatorcontrib><creatorcontrib>Itokawa, Norio</creatorcontrib><creatorcontrib>Okubo, Tomomi</creatorcontrib><creatorcontrib>Arai, Taeang</creatorcontrib><creatorcontrib>Imai, Michitaka</creatorcontrib><creatorcontrib>Kosaka, Hisashi</creatorcontrib><creatorcontrib>Naganuma, Atsushi</creatorcontrib><creatorcontrib>Koizumi, Yohei</creatorcontrib><creatorcontrib>Nakamura, Shinichiro</creatorcontrib><creatorcontrib>Kaibori, Masaki</creatorcontrib><creatorcontrib>Iijima, Hiroko</creatorcontrib><creatorcontrib>Hiasa, Yoichi</creatorcontrib><creatorcontrib>Persano, Mara</creatorcontrib><creatorcontrib>Camera, Silvia</creatorcontrib><creatorcontrib>Foti, Silvia</creatorcontrib><creatorcontrib>Aldrighetti, Luca</creatorcontrib><creatorcontrib>Cascinu, Stefano</creatorcontrib><creatorcontrib>Casadei‐Gardini, Andrea</creatorcontrib><creatorcontrib>Piscaglia, Fabio</creatorcontrib><title>Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Introduction
Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short‐mid term in advanced tumours is unclear. The present analysis investigates the role of BMI weight classes in a large sample of patients affected by HCC and receiving atezolizumab plus bevacizumab or lenvatinib as first‐line treatment.
Methods and Material
The cohort included consecutive patients affected by BCLC‐c and BCLC‐B HCC patients from a multicenter international study group who received atezolizumab plus bevacizumab or lenvatinib as first‐line therapy. Population was stratified according to the BMI in under‐, over‐ and normal‐weight according to the conventional thresholds.
The primary objective of the study was to evaluate the prognostic and predictive impact of BMI in patients affected by advanced or intermediate HCC. Survival curves were estimated using the product‐limit method of Kaplan–Meier. The role of stratification factors was analysed with log‐rank tests.
Results
1292 consecutive patients with HCC were analysed. 466 (36%) patients were treated with lenvatinib and 826 (64%) patients were treated with atezolizumab plus bevacizumab. In the atezolizumab plus bevacizumab arm, 510 (62%) patients were normal‐weight, 52 (6%) underweight and 264 (32%) overweight. At the univariate analysis for OS, underweight patients had significantly shorter OS compared to normal‐weight patients, whereas no differences were found between normal‐weight versus overweight. Multivariate analysis confirmed that underweight patients had significantly shorter OS compared to normal‐weight patients (HR: 1.7; 95% CI: 1.0–2.8; p = .0323). In the lenvatinib arm, 26 patients (5.6%) were categorized as underweight, 256 (54.9%) as normal‐weight, and 184 (39.5%) as overweight. At the univariate analysis for OS, no significant differences were found between normal‐weight versus underweight and between normal‐weight versus overweight, which was confirmed at multivariate analysis.
Conclusion
Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib.</description><subject>advanced HCC</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>atezolizumab</subject><subject>Bevacizumab</subject><subject>Body Mass Index</subject><subject>Body size</subject><subject>Body weight</subject><subject>Carcinoma, Hepatocellular</subject><subject>Cohorts</subject><subject>Humans</subject><subject>International studies</subject><subject>lenvatinib BMI</subject><subject>Liver Neoplasms</subject><subject>Medical prognosis</subject><subject>Multivariate analysis</subject><subject>Overweight</subject><subject>Phenylurea Compounds</subject><subject>Prognosis</subject><subject>Quinolines</subject><subject>Rank tests</subject><subject>Stratification</subject><subject>Thinness</subject><subject>Underweight</subject><subject>Weight</subject><issn>1478-3223</issn><issn>1478-3231</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10b1uFDEUBWALEZEQKHgBZIkmFJv4jj1_JVoRstJKaYDW8niugyOPPdgzGzZV6lQ8I0-Cw4QUSLixZX06uleHkDfATiGfM2d3p1A2TfmMHIGomxUvODx_ehf8kLxM6ZoxaNsSXpBD3pRQF011RO43w6j0RIOhXej3dFApUet7_EGDp9M3pGMMVz4kmx7M7CMm1JPqHNKL9ZqOarLop0QjarQ766-osTFNv-5-OuuRbtHvMvG2oyFSNeFtcPZ2HlRHRzcn2uFO6eXjFTkwyiV8_Xgfky_nHz-vL1bby0-b9YftSnPg5coIAUwIZWrDG9P1indNDaY1LWt5hRo077GvtWI9FAqF5iW0CsoKmg4qMPyYnCy5ebPvM6ZJDjZpdE55DHOSRVsLxnhbF5m--4dehzn6PJ3kTDDOq0qIrN4vSseQUkQjx2gHFfcSmHwoSOaC5J-Csn37mDh3A_ZP8m8jGZwt4MY63P8_SW43X5fI312AnT0</recordid><startdate>202405</startdate><enddate>202405</enddate><creator>Rimini, Margherita</creator><creator>Stefanini, Bernardo</creator><creator>Tada, Toshifumi</creator><creator>Suda, Goki</creator><creator>Shimose, Shigeo</creator><creator>Kudo, Masatoshi</creator><creator>Finkelmeier, Fabian</creator><creator>Yoo, Changhoon</creator><creator>Presa, José</creator><creator>Amadeo, Elisabeth</creator><creator>genovesi, Virginia</creator><creator>De Grandis, Maria Caterina</creator><creator>Iavarone, Massimo</creator><creator>Marra, Fabio</creator><creator>Foschi, Francesco</creator><creator>Tamburini, Emiliano</creator><creator>Rossari, Federico</creator><creator>Vitiello, Francesco</creator><creator>Bartalini, Linda</creator><creator>Soldà, Caterina</creator><creator>Tovoli, Francesco</creator><creator>Vivaldi, Caterina</creator><creator>Lonardi, Sara</creator><creator>Silletta, Marianna</creator><creator>Kumada, Takashi</creator><creator>Sakamoto, Naoya</creator><creator>Iwamoto, Hideki</creator><creator>Aoki, Tomoko</creator><creator>Himmelsbach, Vera</creator><creator>Montes, Margarida</creator><creator>Hiraoka, Atsushi</creator><creator>Sho, Takuya</creator><creator>Niizeki, Takashi</creator><creator>Nishida, Naoshi</creator><creator>Steup, Christoph</creator><creator>Hirooka, Masashi</creator><creator>Kariyama, Kazuya</creator><creator>Tani, Joji</creator><creator>Atsukawa, Masanori</creator><creator>Takaguchi, Koichi</creator><creator>Itobayashi, Ei</creator><creator>Fukunishi, Shinya</creator><creator>Tsuji, Kunihiko</creator><creator>Ishikawa, Toru</creator><creator>Tajiri, Kazuto</creator><creator>Ochi, Hironori</creator><creator>Yasuda, Satoshi</creator><creator>Toyoda, Hidenori</creator><creator>Ogawa, Chikara</creator><creator>Nishimura, Takashi</creator><creator>Hatanaka, Takeshi</creator><creator>Kakizaki, Satoru</creator><creator>Shimada, Noritomo</creator><creator>Kawata, Kazuhito</creator><creator>Tada, Fujimasa</creator><creator>Ohama, Hideko</creator><creator>Nouso, Kazuhiro</creator><creator>Morishita, Asahiro</creator><creator>Tsutsui, Akemi</creator><creator>Nagano, Takuya</creator><creator>Itokawa, Norio</creator><creator>Okubo, Tomomi</creator><creator>Arai, Taeang</creator><creator>Imai, Michitaka</creator><creator>Kosaka, Hisashi</creator><creator>Naganuma, Atsushi</creator><creator>Koizumi, Yohei</creator><creator>Nakamura, Shinichiro</creator><creator>Kaibori, Masaki</creator><creator>Iijima, Hiroko</creator><creator>Hiasa, Yoichi</creator><creator>Persano, Mara</creator><creator>Camera, Silvia</creator><creator>Foti, Silvia</creator><creator>Aldrighetti, Luca</creator><creator>Cascinu, Stefano</creator><creator>Casadei‐Gardini, Andrea</creator><creator>Piscaglia, Fabio</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2373-8601</orcidid><orcidid>https://orcid.org/0000-0002-2018-0008</orcidid><orcidid>https://orcid.org/0000-0003-3656-285X</orcidid><orcidid>https://orcid.org/0000-0002-0760-3045</orcidid><orcidid>https://orcid.org/0000-0003-2211-495X</orcidid><orcidid>https://orcid.org/0000-0003-0098-9106</orcidid><orcidid>https://orcid.org/0000-0002-0976-6761</orcidid><orcidid>https://orcid.org/0000-0002-1652-6168</orcidid><orcidid>https://orcid.org/0000-0002-1882-824X</orcidid><orcidid>https://orcid.org/0000-0002-4986-8578</orcidid><orcidid>https://orcid.org/0000-0003-3374-7111</orcidid><orcidid>https://orcid.org/0000-0002-2266-2414</orcidid><orcidid>https://orcid.org/0000-0003-4117-339X</orcidid><orcidid>https://orcid.org/0000-0001-8264-1845</orcidid><orcidid>https://orcid.org/0000-0003-0224-7093</orcidid><orcidid>https://orcid.org/0000-0001-8629-0878</orcidid><orcidid>https://orcid.org/0000-0001-8559-9910</orcidid><orcidid>https://orcid.org/0000-0003-2068-8386</orcidid><orcidid>https://orcid.org/0000-0001-7415-5898</orcidid><orcidid>https://orcid.org/0000-0002-8350-1155</orcidid><orcidid>https://orcid.org/0000-0002-4102-3474</orcidid><orcidid>https://orcid.org/0000-0003-3493-6504</orcidid><orcidid>https://orcid.org/0000-0003-3800-5678</orcidid><orcidid>https://orcid.org/0000-0002-4047-2585</orcidid></search><sort><creationdate>202405</creationdate><title>Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab</title><author>Rimini, Margherita ; Stefanini, Bernardo ; Tada, Toshifumi ; Suda, Goki ; Shimose, Shigeo ; Kudo, Masatoshi ; Finkelmeier, Fabian ; Yoo, Changhoon ; Presa, José ; Amadeo, Elisabeth ; genovesi, Virginia ; De Grandis, Maria Caterina ; Iavarone, Massimo ; Marra, Fabio ; Foschi, Francesco ; Tamburini, Emiliano ; Rossari, Federico ; Vitiello, Francesco ; Bartalini, Linda ; Soldà, Caterina ; Tovoli, Francesco ; Vivaldi, Caterina ; Lonardi, Sara ; Silletta, Marianna ; Kumada, Takashi ; Sakamoto, Naoya ; Iwamoto, Hideki ; Aoki, Tomoko ; Himmelsbach, Vera ; Montes, Margarida ; Hiraoka, Atsushi ; Sho, Takuya ; Niizeki, Takashi ; Nishida, Naoshi ; Steup, Christoph ; Hirooka, Masashi ; Kariyama, Kazuya ; Tani, Joji ; Atsukawa, Masanori ; Takaguchi, Koichi ; Itobayashi, Ei ; Fukunishi, Shinya ; Tsuji, Kunihiko ; Ishikawa, Toru ; Tajiri, Kazuto ; Ochi, Hironori ; Yasuda, Satoshi ; Toyoda, Hidenori ; Ogawa, Chikara ; Nishimura, Takashi ; Hatanaka, Takeshi ; Kakizaki, Satoru ; Shimada, Noritomo ; Kawata, Kazuhito ; Tada, Fujimasa ; Ohama, Hideko ; Nouso, Kazuhiro ; Morishita, Asahiro ; Tsutsui, Akemi ; Nagano, Takuya ; Itokawa, Norio ; Okubo, Tomomi ; Arai, Taeang ; Imai, Michitaka ; Kosaka, Hisashi ; Naganuma, Atsushi ; Koizumi, Yohei ; Nakamura, Shinichiro ; Kaibori, Masaki ; Iijima, Hiroko ; Hiasa, Yoichi ; Persano, Mara ; Camera, Silvia ; Foti, Silvia ; Aldrighetti, Luca ; Cascinu, Stefano ; Casadei‐Gardini, Andrea ; Piscaglia, Fabio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3135-f441044af7f38fbda3b871f9f90936ec1c3ded7ca0d12ae4c3519a15618b161f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>advanced HCC</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>atezolizumab</topic><topic>Bevacizumab</topic><topic>Body Mass Index</topic><topic>Body size</topic><topic>Body weight</topic><topic>Carcinoma, Hepatocellular</topic><topic>Cohorts</topic><topic>Humans</topic><topic>International studies</topic><topic>lenvatinib BMI</topic><topic>Liver Neoplasms</topic><topic>Medical prognosis</topic><topic>Multivariate analysis</topic><topic>Overweight</topic><topic>Phenylurea Compounds</topic><topic>Prognosis</topic><topic>Quinolines</topic><topic>Rank tests</topic><topic>Stratification</topic><topic>Thinness</topic><topic>Underweight</topic><topic>Weight</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rimini, Margherita</creatorcontrib><creatorcontrib>Stefanini, Bernardo</creatorcontrib><creatorcontrib>Tada, Toshifumi</creatorcontrib><creatorcontrib>Suda, Goki</creatorcontrib><creatorcontrib>Shimose, Shigeo</creatorcontrib><creatorcontrib>Kudo, Masatoshi</creatorcontrib><creatorcontrib>Finkelmeier, Fabian</creatorcontrib><creatorcontrib>Yoo, Changhoon</creatorcontrib><creatorcontrib>Presa, José</creatorcontrib><creatorcontrib>Amadeo, Elisabeth</creatorcontrib><creatorcontrib>genovesi, Virginia</creatorcontrib><creatorcontrib>De Grandis, Maria Caterina</creatorcontrib><creatorcontrib>Iavarone, Massimo</creatorcontrib><creatorcontrib>Marra, Fabio</creatorcontrib><creatorcontrib>Foschi, Francesco</creatorcontrib><creatorcontrib>Tamburini, Emiliano</creatorcontrib><creatorcontrib>Rossari, Federico</creatorcontrib><creatorcontrib>Vitiello, Francesco</creatorcontrib><creatorcontrib>Bartalini, Linda</creatorcontrib><creatorcontrib>Soldà, Caterina</creatorcontrib><creatorcontrib>Tovoli, Francesco</creatorcontrib><creatorcontrib>Vivaldi, Caterina</creatorcontrib><creatorcontrib>Lonardi, Sara</creatorcontrib><creatorcontrib>Silletta, Marianna</creatorcontrib><creatorcontrib>Kumada, Takashi</creatorcontrib><creatorcontrib>Sakamoto, Naoya</creatorcontrib><creatorcontrib>Iwamoto, Hideki</creatorcontrib><creatorcontrib>Aoki, Tomoko</creatorcontrib><creatorcontrib>Himmelsbach, Vera</creatorcontrib><creatorcontrib>Montes, Margarida</creatorcontrib><creatorcontrib>Hiraoka, Atsushi</creatorcontrib><creatorcontrib>Sho, Takuya</creatorcontrib><creatorcontrib>Niizeki, Takashi</creatorcontrib><creatorcontrib>Nishida, Naoshi</creatorcontrib><creatorcontrib>Steup, Christoph</creatorcontrib><creatorcontrib>Hirooka, Masashi</creatorcontrib><creatorcontrib>Kariyama, Kazuya</creatorcontrib><creatorcontrib>Tani, Joji</creatorcontrib><creatorcontrib>Atsukawa, Masanori</creatorcontrib><creatorcontrib>Takaguchi, Koichi</creatorcontrib><creatorcontrib>Itobayashi, Ei</creatorcontrib><creatorcontrib>Fukunishi, Shinya</creatorcontrib><creatorcontrib>Tsuji, Kunihiko</creatorcontrib><creatorcontrib>Ishikawa, Toru</creatorcontrib><creatorcontrib>Tajiri, Kazuto</creatorcontrib><creatorcontrib>Ochi, Hironori</creatorcontrib><creatorcontrib>Yasuda, Satoshi</creatorcontrib><creatorcontrib>Toyoda, Hidenori</creatorcontrib><creatorcontrib>Ogawa, Chikara</creatorcontrib><creatorcontrib>Nishimura, Takashi</creatorcontrib><creatorcontrib>Hatanaka, Takeshi</creatorcontrib><creatorcontrib>Kakizaki, Satoru</creatorcontrib><creatorcontrib>Shimada, Noritomo</creatorcontrib><creatorcontrib>Kawata, Kazuhito</creatorcontrib><creatorcontrib>Tada, Fujimasa</creatorcontrib><creatorcontrib>Ohama, Hideko</creatorcontrib><creatorcontrib>Nouso, Kazuhiro</creatorcontrib><creatorcontrib>Morishita, Asahiro</creatorcontrib><creatorcontrib>Tsutsui, Akemi</creatorcontrib><creatorcontrib>Nagano, Takuya</creatorcontrib><creatorcontrib>Itokawa, Norio</creatorcontrib><creatorcontrib>Okubo, Tomomi</creatorcontrib><creatorcontrib>Arai, Taeang</creatorcontrib><creatorcontrib>Imai, Michitaka</creatorcontrib><creatorcontrib>Kosaka, Hisashi</creatorcontrib><creatorcontrib>Naganuma, Atsushi</creatorcontrib><creatorcontrib>Koizumi, Yohei</creatorcontrib><creatorcontrib>Nakamura, Shinichiro</creatorcontrib><creatorcontrib>Kaibori, Masaki</creatorcontrib><creatorcontrib>Iijima, Hiroko</creatorcontrib><creatorcontrib>Hiasa, Yoichi</creatorcontrib><creatorcontrib>Persano, Mara</creatorcontrib><creatorcontrib>Camera, Silvia</creatorcontrib><creatorcontrib>Foti, Silvia</creatorcontrib><creatorcontrib>Aldrighetti, Luca</creatorcontrib><creatorcontrib>Cascinu, Stefano</creatorcontrib><creatorcontrib>Casadei‐Gardini, Andrea</creatorcontrib><creatorcontrib>Piscaglia, Fabio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rimini, Margherita</au><au>Stefanini, Bernardo</au><au>Tada, Toshifumi</au><au>Suda, Goki</au><au>Shimose, Shigeo</au><au>Kudo, Masatoshi</au><au>Finkelmeier, Fabian</au><au>Yoo, Changhoon</au><au>Presa, José</au><au>Amadeo, Elisabeth</au><au>genovesi, Virginia</au><au>De Grandis, Maria Caterina</au><au>Iavarone, Massimo</au><au>Marra, Fabio</au><au>Foschi, Francesco</au><au>Tamburini, Emiliano</au><au>Rossari, Federico</au><au>Vitiello, Francesco</au><au>Bartalini, Linda</au><au>Soldà, Caterina</au><au>Tovoli, Francesco</au><au>Vivaldi, Caterina</au><au>Lonardi, Sara</au><au>Silletta, Marianna</au><au>Kumada, Takashi</au><au>Sakamoto, Naoya</au><au>Iwamoto, Hideki</au><au>Aoki, Tomoko</au><au>Himmelsbach, Vera</au><au>Montes, Margarida</au><au>Hiraoka, Atsushi</au><au>Sho, Takuya</au><au>Niizeki, Takashi</au><au>Nishida, Naoshi</au><au>Steup, Christoph</au><au>Hirooka, Masashi</au><au>Kariyama, Kazuya</au><au>Tani, Joji</au><au>Atsukawa, Masanori</au><au>Takaguchi, Koichi</au><au>Itobayashi, Ei</au><au>Fukunishi, Shinya</au><au>Tsuji, Kunihiko</au><au>Ishikawa, Toru</au><au>Tajiri, Kazuto</au><au>Ochi, Hironori</au><au>Yasuda, Satoshi</au><au>Toyoda, Hidenori</au><au>Ogawa, Chikara</au><au>Nishimura, Takashi</au><au>Hatanaka, Takeshi</au><au>Kakizaki, Satoru</au><au>Shimada, Noritomo</au><au>Kawata, Kazuhito</au><au>Tada, Fujimasa</au><au>Ohama, Hideko</au><au>Nouso, Kazuhiro</au><au>Morishita, Asahiro</au><au>Tsutsui, Akemi</au><au>Nagano, Takuya</au><au>Itokawa, Norio</au><au>Okubo, Tomomi</au><au>Arai, Taeang</au><au>Imai, Michitaka</au><au>Kosaka, Hisashi</au><au>Naganuma, Atsushi</au><au>Koizumi, Yohei</au><au>Nakamura, Shinichiro</au><au>Kaibori, Masaki</au><au>Iijima, Hiroko</au><au>Hiasa, Yoichi</au><au>Persano, Mara</au><au>Camera, Silvia</au><au>Foti, Silvia</au><au>Aldrighetti, Luca</au><au>Cascinu, Stefano</au><au>Casadei‐Gardini, Andrea</au><au>Piscaglia, Fabio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2024-05</date><risdate>2024</risdate><volume>44</volume><issue>5</issue><spage>1108</spage><epage>1125</epage><pages>1108-1125</pages><issn>1478-3223</issn><issn>1478-3231</issn><eissn>1478-3231</eissn><abstract>Introduction
Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short‐mid term in advanced tumours is unclear. The present analysis investigates the role of BMI weight classes in a large sample of patients affected by HCC and receiving atezolizumab plus bevacizumab or lenvatinib as first‐line treatment.
Methods and Material
The cohort included consecutive patients affected by BCLC‐c and BCLC‐B HCC patients from a multicenter international study group who received atezolizumab plus bevacizumab or lenvatinib as first‐line therapy. Population was stratified according to the BMI in under‐, over‐ and normal‐weight according to the conventional thresholds.
The primary objective of the study was to evaluate the prognostic and predictive impact of BMI in patients affected by advanced or intermediate HCC. Survival curves were estimated using the product‐limit method of Kaplan–Meier. The role of stratification factors was analysed with log‐rank tests.
Results
1292 consecutive patients with HCC were analysed. 466 (36%) patients were treated with lenvatinib and 826 (64%) patients were treated with atezolizumab plus bevacizumab. In the atezolizumab plus bevacizumab arm, 510 (62%) patients were normal‐weight, 52 (6%) underweight and 264 (32%) overweight. At the univariate analysis for OS, underweight patients had significantly shorter OS compared to normal‐weight patients, whereas no differences were found between normal‐weight versus overweight. Multivariate analysis confirmed that underweight patients had significantly shorter OS compared to normal‐weight patients (HR: 1.7; 95% CI: 1.0–2.8; p = .0323). In the lenvatinib arm, 26 patients (5.6%) were categorized as underweight, 256 (54.9%) as normal‐weight, and 184 (39.5%) as overweight. At the univariate analysis for OS, no significant differences were found between normal‐weight versus underweight and between normal‐weight versus overweight, which was confirmed at multivariate analysis.
Conclusion
Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38517286</pmid><doi>10.1111/liv.15885</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0002-2373-8601</orcidid><orcidid>https://orcid.org/0000-0002-2018-0008</orcidid><orcidid>https://orcid.org/0000-0003-3656-285X</orcidid><orcidid>https://orcid.org/0000-0002-0760-3045</orcidid><orcidid>https://orcid.org/0000-0003-2211-495X</orcidid><orcidid>https://orcid.org/0000-0003-0098-9106</orcidid><orcidid>https://orcid.org/0000-0002-0976-6761</orcidid><orcidid>https://orcid.org/0000-0002-1652-6168</orcidid><orcidid>https://orcid.org/0000-0002-1882-824X</orcidid><orcidid>https://orcid.org/0000-0002-4986-8578</orcidid><orcidid>https://orcid.org/0000-0003-3374-7111</orcidid><orcidid>https://orcid.org/0000-0002-2266-2414</orcidid><orcidid>https://orcid.org/0000-0003-4117-339X</orcidid><orcidid>https://orcid.org/0000-0001-8264-1845</orcidid><orcidid>https://orcid.org/0000-0003-0224-7093</orcidid><orcidid>https://orcid.org/0000-0001-8629-0878</orcidid><orcidid>https://orcid.org/0000-0001-8559-9910</orcidid><orcidid>https://orcid.org/0000-0003-2068-8386</orcidid><orcidid>https://orcid.org/0000-0001-7415-5898</orcidid><orcidid>https://orcid.org/0000-0002-8350-1155</orcidid><orcidid>https://orcid.org/0000-0002-4102-3474</orcidid><orcidid>https://orcid.org/0000-0003-3493-6504</orcidid><orcidid>https://orcid.org/0000-0003-3800-5678</orcidid><orcidid>https://orcid.org/0000-0002-4047-2585</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2024-05, Vol.44 (5), p.1108-1125 |
| issn | 1478-3223 1478-3231 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2974003972 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | advanced HCC Antibodies, Monoclonal, Humanized atezolizumab Bevacizumab Body Mass Index Body size Body weight Carcinoma, Hepatocellular Cohorts Humans International studies lenvatinib BMI Liver Neoplasms Medical prognosis Multivariate analysis Overweight Phenylurea Compounds Prognosis Quinolines Rank tests Stratification Thinness Underweight Weight |
| title | Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T10%3A12%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20body%20mass%20index%20on%20the%20prognosis%20of%20unresectable%20HCC%20patients%20receiving%20first%E2%80%90line%20Lenvatinib%20or%20atezolizumab%20plus%20bevacizumab&rft.jtitle=Liver%20international&rft.au=Rimini,%20Margherita&rft.date=2024-05&rft.volume=44&rft.issue=5&rft.spage=1108&rft.epage=1125&rft.pages=1108-1125&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.15885&rft_dat=%3Cproquest_cross%3E2974003972%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3040336644&rft_id=info:pmid/38517286&rfr_iscdi=true |